annb0t
Top 20
Immutep Limited
Media Release
20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination therapy study of efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy Promising initial efficacy results showing a 72.7% response rate and 90.9% disease control rate reported at SITC 2022 Additional data is expected throughout calendar year 2023 and will further inform our next steps in 1L NSCLC
SYDNEY, AUSTRALIA, Feb. 06, 2023 (GLO...
>>> Read more: Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Media Release
20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination therapy study of efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy Promising initial efficacy results showing a 72.7% response rate and 90.9% disease control rate reported at SITC 2022 Additional data is expected throughout calendar year 2023 and will further inform our next steps in 1L NSCLC
SYDNEY, AUSTRALIA, Feb. 06, 2023 (GLO...
>>> Read more: Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
